文献速递青光眼眼底病与葡萄膜炎

PRMT5通过靶向Wnt/β-连环蛋白信号级联调控视网膜神经节细胞衰老

PRMT5 Regulates Senescence in Retinal Ganglion Cells by Targeting the Wnt/β-Catenin Signaling Cascade.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

在慢性高眼压(COH)小鼠模型中,PRMT5在视网膜神经节细胞(RGC)中显著下调,与眼压升高诱导的RGC衰老增加相关;沉默PRMT5加速衰老,而GSK3β抑制剂CHIR99021可减轻缺氧诱导的衰老并重新激活Wnt/β-连环蛋白通路;体内PRMT5抑制剂GSK3326595降低RGC存活并增加衰老标志物,CHIR99021则减轻RGC丢失并恢复Wnt/β-连环蛋白信号。

要点

  • COH小鼠RGC中PRMT5显著下调,与眼压升高诱导的RGC衰老增加相关。
  • 沉默PRMT5加速衰老,表现为SA-β-gal活性增加、细胞周期停滞和衰老标志物上调。
  • CHIR99021减轻缺氧诱导的衰老并重新激活Wnt/β-连环蛋白通路,GSK3326595降低RGC存活并增加衰老标志物。

核心结论

  • PRMT5调控的Wnt/β-连环蛋白通路在RGC衰老和神经变性中起关键作用,靶向该通路是青光眼有前景的治疗策略。

研究设计与样本

  • 研究建立慢性高眼压(COH)小鼠模型,通过前房注射交联水凝胶实现。
  • 采用Western blot、细胞周期分析、衰老相关β-半乳糖苷酶(SA-β-gal)染色、酶联免疫吸附试验和免疫荧光评估细胞衰老。
  • 在视网膜前体(R28)细胞中通过小干扰RNA介导的敲低和质粒介导的过表达进行功能实验。
  • 通过小鼠玻璃体内注射GSK3326595和CHIR99021研究PRMT5调控的Wnt/β-连环蛋白通路在RGC衰老中的作用。

主要发现

  • 在COH小鼠模型中,PRMT5在RGC中显著下调,与眼压升高诱导的RGC衰老增加相关。
  • 沉默PRMT5显著加速衰老,表现为SA-β-gal活性增加、细胞周期停滞和衰老标志物上调。
  • GSK3β抑制剂CHIR99021共处理减轻缺氧诱导的衰老并重新激活Wnt/β-连环蛋白通路,而拮抗剂FH535抵消PRMT5过表达的神经保护作用。
  • 体内PRMT5抑制剂GSK3326595降低RGC存活并增加衰老标志物,而CHIR99021减轻RGC丢失并恢复Wnt/β-连环蛋白信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with glaucoma, progressive degeneration of retinal ganglion cells (RGCs) leads to irreversible visual impairments. Despite recent studies indicating that senescence is associated with RGC death, the underlying molecular mechanisms remain unclear. METHODS: The chronic ocular hypertension (COH) mouse model was established by infusing a crosslinking hydrogel into the anterior chamber. Cellular senescence was evaluated using Western blot analysis, cell cycle, senescence-associated β-galactosidase (SA-β-gal) staining, enzyme-linked immunosorbent assay, and immunofluorescence. Functional experiments were conducted in retinal precursor (R28) cells through small interfering RNA-mediated knockdown and plasmid-mediated overexpression. Additionally, the role of the protein arginine methyltransferase 5 (PRMT5)-regulated Wnt/β-catenin pathway in RGC senescence was investigated via intravitreal injection of GSK3326595 and CHIR99021 in mice. RESULTS: We demonstrate that PRMT5 is markedly downregulated in RGC in a COH mouse model, correlating with increased RGC senescence induced by elevated intraocular pressure. Silencing PRMT5 significantly accelerated senescence, as evidenced by increased SA-β-gal activity, cell cycle arrest, and senescence marker upregulation. Cotreatment with GSK3β inhibitor CHIR99021 alleviated hypoxia-induced senescence and reactivated the Wnt/β-catenin pathway, while the antagonist FH535 negated the neuroprotective effects of PRMT5 overexpression. In vivo, the PRMT5 inhibitor GSK3326595 reduced RGC survival and heightened senescence markers, whereas CHIR99021 mitigated RGC loss and restored Wnt/β-catenin signaling. CONCLUSIONS: Taken together, these findings highlight the critical role of the PRMT5-regulated Wnt/β-catenin pathway in RGC senescence and neurodegeneration. Targeting this pathway represents a promising therapeutic strategy for glaucoma.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Huang H, Zhong H, et al. PRMT5 Regulates Senescence in Retinal Ganglion Cells by Targeting the Wnt/β-Catenin Signaling Cascade. Invest Ophthalmol Vis Sci. 2025. PMID: 40459496. doi:10.1167/iovs.66.6.8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。